Factors of tubulointerstitial lesions in diabetic kidneys
https://doi.org/10.14341/2072-0351-5707
Abstract
As the number of cases with classical manifestations of diabetic nephropathy (DN), i.e. nodular or diffuse glomerulosclerosis, grows, an increasinglylarger number of DM patients especially those with DM2 present with renal pathology largely affecting interstitium and tubules (ischemic nephropathy,urinary infection, interstitial nephritis, etc.). The rate of renal filtration impairment in glomerular diseases (DN, glomerulonephritis) is also relatedto the severity of tubulointerstitial fibrosis (TIF). Intricate intercellular interactions activated by immune and non-immune factors have been shownto play an important role in the development of tubulointerstitial lesions. Studies of the most important factors contributing to remodeling tubulointerstitiumin DM patients may provide a deeper insight into the mechanisms of nephrosclerosis and extend possibilities for prognostication of renalfunction.
About the Authors
Minara Shamkhalovna Shamkhalova
Endocrinology Research Centre, Moscow
Kseniya Olegovna Kurumova
Endocrinology Research Centre, Moscow
Marina Vladimirovna Shestakova
Endocrinology Research Centre, Moscow
References
1. Шестакова М.В., Дедов И.И. Сахарный диабет и хроническая болезнь почек: Медицинское Информационное Агентство, 2009 г.
2. Meier P., Rossert J., Plouin P.-F., Burnier M. Atherosclerotic renovascular disease: beyond the renal artery stenosis // Nephrology Dialysis Transplantation. - 2007. - 22(4). - Р.1002-1006.
3. Ina K., Kitamura H., Tatsukawa Sh. Transformation of interstitial fibroblasts and tubulointerstitial fibrosis in diabetic nephropathy // Medical. Electron. Microscopy. - 2002. - 35. - Р. 87-95.
4. Ellis D., Fottest K.Y., Erbey J. Urinary measurement of transforming growth factor- beta and type IV collagen as a new markers of renal injury: Application in diabetic nephropathy // Clinical Chemistry. - 1998. - 44. - Р.950-56.
5. Benigni A., Tomasoni S., Gagliardini E. Blocking angiotensin II synthesis / activity preserves Glomerular nephrin in rats with severe nephrosis // J. Am. Soc. Nephrology. - 2001. - 12. - Р.941-948.
6. Sugomoto H., Grahovae G., Zeisberg M. et al. Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors // Diabetes. - 2007. - 56. - Р. 1825-1833.
7. Ninichuk V., Kulkarni O., Clauss S. Tubular atrophy, interstitial fibrosis and inflammation in type 2 diabetic db/db mice. An accelerated model of advanced diabetic nephropathy // European journal of medical research. - 2007. - 12(8). - Р.351-355.
8. Kim J.G, Lee J., Roe J., Tromberg B.J., Brenner M., Walters T.J. Hemodynamic changes in rat leg muscles during tourniquet-induced ischemia-reperfusion injury observed by near-infrared spectroscopy // Physiologycal Measurement. - 2009. - Jul.; 30(7). - Р. 529-540.
9. Annes J.P., Munger J.S., Rifkin D.B. Making sense of latent TGF- activation // Journal of Cell Science. - 2003. - 116. - Р. 217-224.
10. Sato Y., Rifkin D.B. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor- 1-like molecule by plasmin during co-culture // Journal of Cell Biol. - 1989. - 109. - Р. 309-315.
11. Yu Q., Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF- and promotes tumor invasion and angiogenesis // Genes and Development. - 2000. - 14. - Р. 163-176.
12. Schultz-Cherry S., Murphy-Ullrich J.E. Thrombospondin causes activation of latent transforming growth factor-beta secreted by endothelial cells by a novel mechanism // Journal of Cell Biol. 1993; 122, 923-32.
13. Frazier W.A. Thrombospondins // Curr. Opin. Cell Biol. - 1991. - 3. - Р.792-99.
14. Varga J., Jimenez S.A. Stimulation of normal human fibroblast collagen production and processing by transforming growth factor-beta // Biochemical and biophysical research communications. - 1986. - 138. - Р.974-80.
15. Overall C.M., Wrana J.L., Sodek J. Independent regulation of collagenase, 72-kDa progelatinase, and metalloendoproteinase inhibitor expression in human fibroblasts by transforming growth factor-beta // The Journal of biological chemistry. - 1989. - 264. - Р.1860-1869.
16. Diez-Marques L., Ortega-Velazquez R., Langa C. Expression of endoglin in human mesangial cells: modulation of extracellular matrix synthesis // Biochim Biophys Acta. - 2002. - 21, 1587(1). - Р.36-44.
17. Ledbetter S., Kurtzberg L., Doyle S., Pratt B.M. Renal fibrosis in mice treated with human recombinant transforming growth factor-beta2 // Kidney Int. - 2000. - 58(6). - Р.2367-2376.
18. Mozes M.M., Bottenger E.P., Jacot T.A. Renal expression of fibrotic matrix proteins and transforming factor -beta isoforms in TGF- transgenic mice // J. Am. Soc. Nephrology. - 1999. - 10(2). - Р.271- 280.
19. Nabel E.G., Shum L., Pompili V.J. Direct transfer transforming growth factor - beta 1 gene into arteries stimulates of fibrocellular hyperplasia // Proc. Natl. Acad. Sci. USA. - 1993. - 90. - Р.10759-10769.
20. Saltis J., Agrotis A., Bobil A. Regulation and interaction of transforming growth factor - beta 1 with cardiovascular cells: implications of development and disease // Clinical and experimental pharmacology and physiology. - 1996. - 23. - Р.193-200.
21. Ina K., Kitamura H., Tatsukawa S. Transformation of interstitial fibroblasts and tubulointerstitial fibrosis in diabetic nephropathy Medical Electron Microscopy. - 2002. - 35(2). - Р.87-95.
22. Branton M.H., Kopp J.B. TGF-beta and fibrosis // Microbes. Infect. - 1999. - 1(15). - Р.1349-1365.
23. Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases // The Journal of Pathology 2003; 200, 500-503.
24. Powell D.W., Bertram C.C., Cummins T.D. Renal tubulointerstitial fibrosis in OVE26 diabetic mice // Nephron. Exp. Nephrol. - 2009. - 111. - Р.11-19.
25. Nguyen T.Q., Tarnow L., Jorsal A., Roestenberg, P., Yasuhiko I., Parving H.-H., Rossing P., Frans A. van Nieuwenhoven, Goldschmeding R. Plasma сconnective tissue growth factor is an independent Predictor of End-Stage Renal Disease and Mortality in Type 1 Diabetic Nephropathy // Diabetes Care. - 2008. - Jun.; 31(6). - Р.1177-82.
26. Kobayashi T., Okada H., Inoue T., Kanno Y., Suzuki H. Tubular expression of connective tissue growth factor correlates with interstitial fibrosis in type 2 diabetic nephropathy. Nephrology Dialysis Transplantation. - 2006. - 21(2). - Р.548-549.
27. Grandaliano G., Gesualdo L., Bartoli F. MCP-1 and EGF renal expression and urine excretion in human congenital obstructive nephropathy // Kidney Int. - 2000. - 58(1). - Р.182-192.
28. Viedt C., Dechend R., Fei J. MCP-1 induces inflammatory activation of human tubular epithelial cells: involvement of the transcription factors, nuclear factor-kappa B and activating protein-1 // J. Am. Soc. Nephrology . - 2002. - 13(6). - Р.1534-47.
29. Mazurek Т., Zапg L.F., Маnniоn J. Local epicardial adipose tissue inflаlamаtiоn is associated with serum insulin аnd insuliln rеsistаnсе in patients with advanced соronагу artery disease // Diabetologia. - 2004. - 47(Suppl. 1). - Р.31.
30. Aukrust Р., Yndestad А., Smith С. Chemokines in cardiоvаsсulаr risk prediction // Arteriosclerosis, Thrombosis, and Vascular Biology. - 2008. - 28. - Р.1909.
31. Braunersreuther V., Масh F., Steffens S. The specific role of сhеmоkinеs in atherosclerosis // Thromb. Haemost. - 2007. - 97(5). - Р.714-721.
32. Coll В., Alоnsо-Villаvеrdе С., Joven J. Monocyte сhеmоаttrасtаnt рrotеin- 1 аnd аthеrosсlеrosis: is there room fоr аn аdditiоnal biomarker? // Clinica Chimica Acta. - 2007. - 383(1-2). - Р.21-29.
33. Itо А., Suganami Т., Мiyamoto У. Role of МAPK phosphatase-1 in the induсtiоn of mоnосytе сhеmоаttrасtаnt рrotеin-1 during the course of adipocyte hурегtroрhу // The Journal of biological chemistry. - 2007. - 282(35). - Р.25445-25452.
34. Кraaijeveld А.О., de Jager S.C., van Berkel T.J. Сhеmоkinеs and atherosclerotic plaque ргоgгеssiоn: towards therapeutic targеting? // Сurrent Pharmaceutical design. - 2007. - 13(10). - Р.1039-1052.
35. Murdolo G., Hammarstedt А., Sаndqvist М. Моnосytе chemoattractant protein-1 in subсutаnеоus abdominal adipose tissue: сhaгасtеrizаtiоn of interstitial соnсеntrаtiоn аnd rеgulаtiоn of gene expression bу insulin //J. Clin. Endocrinol. Ме¬tab. - 2007. - 92(7). - 2688-2695.
36. Pfleger C., Hougaard P., Hansen L. Relation of serum cytokine levels and chemokine levels with HbA1c, C-peptide and proinsulin in patients with newly diagnosed type 1 diabetes mellitus. Results from the Hvidore Study Group // Diabetologia. - 49(Suppl. 1). - Р.282.
37. Tesch G.H., Schwarting A., Rinoshita K. Monocyte chemoattractant protein 1 promotes macrophage-mediated tubular injury, but not Glomerular injury in nephrotoxic serum nephritis. Journal of clinical investigation. - 1999. - 103. - Р.73-80.
38. Бобкова И.Н., Козловская Л.В., Рамеева А.С., Варшавский В.А., Го- литцина Е.П. Клиническое значение определения экскреции с мочой маркеров эндотелиальной дисфункции и факторов ангиогенеза в оценке тубулоинтерстициального фиброза при хроническом гломе- рулонефрите //Терапевтический Архив. - 2007. -79(6). - Р.10-15.
39. Banda N., Nаkаmurа Т., Маtsumuга М. PoslbIe relationship of monосуtе chemoattractant рrotеin-1 with diabetic nephropathy // Кidnеу Int. - 2000. - 58(2). - Р.684-690.
40. Chiarelli Е., Cipollone F., Molm А. Cirсulаting mоnосуtе сhеmоаttгасtаnt рrotеin-I аnd early dеvеloрmеnt of nерhroраthу in type 1 diabetes // Diabetes Саrе. - 2002. - 25(10). - Р.1829-1834.
41. Chow F.Y., Nikolic-Раtеrson D.J., Ma F.Y. Моnоcyte сhеmоаttгасtаnt рrotеin-1-induсеd tissue inflаmmаtiоn is critical for the dеvеlорmеnt of rеnаl injuгу but nоt type 2 diabetes in obese db/db mice // Diabetologia . - 2007. - 50(2). - Р.471-480.
42. Morii Т., Fujita Н., Narita Т. Аssосiаtiоn of mоnосуtе сhеmoаttrасtаnt protein-1 with rеnаl tubular damage in diabetic 1 nephropathy // Journal Diabetes Comp1icatiol1s . - 2003. - 17(1). - Р.11-15.
43. Klimontov V.V., Bondar I.A., Nadeev A.P. Increased urinary excretion of proinflammatory cytokines is associated with renal structural changes in type 1 diabetic patients // Diabetologia 2007; 50 (Suppl 1): S467.
44. Qi X.M., Wu G.Z., Wu Y.G. Renoprotective effect of breviscapine through suppression of renal macrophage recruitment in streptozocin-induced diabetic rats // Nephron Experimental Nephrology. - 2006. - 104. - Р.147-157.
45. Kristiansen O.P., Mandrup - Poulsen T. Interleukin-6 and Diabetes the Good, the bad, or the Indifferent? // Diabetes. - 2005. - (suppl. 2). - S114-124.
46. Saito O., Saito T., Okuda K., Okuda K., Kotoda A., Akimoto T., Ando Y., Muto S., Ishikawa S.E., Kusano E. Serum adiponectin and markers of endothelial injury in hemodialysis patients with arteriosclerosis obliterans // Clinical Experimental Nephrology. - 2008. - 12(1). - Р.58-64.
47. Suzuki D., Miyazaki M., Naka R., Koji T., Yagame M., Jinde K., Endoh M., Nomoto Y., Sakai H. In situ hybridization of interleukin 6 in diabetic nephropathy // Diabetes. - 2009. - 58 (7).
48. Yard B.A., Choranopolus E., Herr D. Regulation of endothelin-1 and transforming growth factor-beta 1 production in cultured proximal tubular cells by albumin and heparin sulphate glycosaminoglycans // Nephrology Dialysis Transplantation. - 2001. - 16. - Р.1769-1775.
49. Бобкова И.Н., Мухин Н.А., Козловская Л.В., Рамеев В.В., Чеботарева Н.Б., Плиева О.К., Щербак А.В., Варшавский В.А., Голитцина Е.П. Ключевая роль ремоделирования тубоинтерстиция в прогрессирование хронической болезни почек // Архив патологии. - 2004. - 66 (6). - Р.16-22.
50. Kumar D., Zimhelmann J., Robertson S., Buns K.D. Tubular and interstitial cell apoptosis in the streptozotocin-diabetic rat kidney // Nephron. Experimental. Nephrology. - 2004. - 96 (3). - Р.77-88.
51. Schmieder R.E., Krekler M. Observational study of blood pressure control and microalbuminuria in type 2 diabetics on irbesartan or irbesartan/HCTZ. MMW Fortschritte der Medizin. - 2005. - 147 (Suppl. 3). - Р.97-101.
52. Parving H.-H., Lehnert H., Brochner-Mortensen J. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes // The New England journal of medicine. - 2001. - 345. - Р.870-878.
53. Opie L.H., Parving H.-H. Diabetic nephropathy. Can renoprotection be extrapolated to cardiovascular protection? // Circulation. - 2002. - 106. - Р.643-645.
54. Liu E., Morimoto M., Kitajima S., Koike T., Yu Y., Shiiki H., Nagata M., Watanabe T., Fan J. Increased expression of vascular endothelial growth factor in kidney leads to progressive impairment of glomerular functions // J. Am. Soc. Nephrology. - 2007. - 18(7). - Р. 2094-2104.
55. Tremolada G., Lattanzio R., Mazzolari G., Zerbini G. The therapeutic potential of VEGF inhibition in diabetic microvascular complications // Am. J. Cardiovascular. Drugs. - 2007. - 7(6). - Р.393-398.
56. Khamaisi M., Bieke F., Schrijvers, A., Vriese S., Itamar R., Flyvbjerg A. The emerging role of VEGF in diabetic kidney disease Nephrology Dialysis Transplantation . - 2003. - 18. - Р.1427-430.
57. Papapetropoulos A., Garcia-Cardena G., Madri J.A, William C.S, Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells The American Society for Clinical Investigation. - 1997. - V.100, №12. - Р.3131-3139.
58. Khamaisi M., Schrijvers B.F., De Vriese An.S., Raz I., Flyvbjerg A. The emerging role of VEGF in diabetic kidney disease // Nephrology Dialy. - Р.1427-430.
59. Pandolfi A., Cetrullo D., Polishuck R., Alberta M.M., Calafiore A., Pellegrini G., Vitacolonna E., Capani F., Consoli A. Plasminogen Activator Inhibitor Type 1 Is Increased in the Arterial Wall of Type II Diabetic Subjects Arteriosclerosis, Thrombosis, and Vascular Biology. - 2001. - 21. - Р. 1378- 1382.
60. Solano M.P., Perry A.C., Wang X., Ross R., Goldberg R.B. Insulin resistance but not visceral adipose tissue is associated with plasminogen activator inhibitor type 1 levels in overweight and obese premenopausal // African- American women International Journal of Obesity. - 2003. - 27. - Р.82-87.
61. Bosevski M., Borozanov V., Peovska I., Georgievska-Ismail L. Endothelial dysfunction correlates with plasma fibrinogen and HDL cholesterol in type 2 diabetic patients with coronary artery disease // Bratisl. Lek. Listy . - 2007. - 108(7). - Р.297-300.
62. Bangstad H.-J., Seljeflot I., Berg T.J. Renal tubulointerstitial expansion is associated with endothelial dysfunction and inflammation in type 1 diabetes // Scandinavian Journal of Clinical and Laboratory Investigation V.69, №1, 2009, P. 138-144(7).
63. Fliser D., Kronenberg F., Kielstein J.T., Morath C., Bode-Boger S.M., Haller H., Ritz E. Asymmetric dimethylarginine and progression of chronic kidney disease: The Mild to Moderate Kidney Disease Study // J. Am. Soc. Nephrology 2005; 16 (8): 2456-61.
64. Brezniceanu M.L., Liu F., Wei C.C. Attenuation of interstitial fibrosis and tubular apoptosis in db/db transgenic mice overexpressing catalase in renal proximal tubular cells // Diabetes 2008; 57: 451-459.
Review
For citations:
Shamkhalova M.Sh., Kurumova K.O., Shestakova M.V. Factors of tubulointerstitial lesions in diabetic kidneys. Diabetes mellitus. 2009;12(4):61-65. (In Russ.) https://doi.org/10.14341/2072-0351-5707
Views:
919
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
